Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates.

Scientific reports - 22 Mar 2021

Bertoli Gloria, Cava Claudia, Corsi Fabio, Piccotti Francesca, Martelli Cristina, Ottobrini Luisa, Vaira Valentina, Castiglioni Isabella

Abstract excerpt

Triple negative breast cancer (TNBC) accounts for about a fifth of all breast cancers and includes a diverse group of cancers. The heterogeneity of TNBC and the lack of target receptors on the cell surface make it difficult to develop specific therapeutic treatments. These aspects cause the high negative prognosis of patients with this type of tumor. The analysis of the molecular profiles of TNBC samples has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Mesenchymal Stem Cells

Share to MicroRNAs

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33753785
DOI: 10.1038/s41598-021-85746-w
PMCID: PMC7985188

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates.PMID 33753785Read ↗

Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control.Semantic proximity Read ↗

MIR4435-2HG: A Novel Biomarker for Triple-Negative Breast Cancer Diagnosis and Prognosis, Driving Tumor Progression through EMT by JNK/c-Jun and p38 MAPK Signaling Pathway ActivationSemantic proximity Read ↗

Targeting basal-like breast cancers.Semantic proximity Read ↗

Coordinated regulation of WNT/β-catenin, c-Met, and Integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traitsSemantic proximity Read ↗

Exploring Molecular Pathways of Triple-Negative Breast CancerSemantic proximity Read ↗

Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.Semantic proximity Read ↗

Integrative Analysis of lncRNA-mRNA Signature Reveals a Functional lincRNA in Triple-negative Breast CancerSemantic proximity Read ↗

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomasSemantic proximity Read ↗

Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential TherapySemantic proximity Read ↗

What Is the Difference Between Triple-Negative and Basal Breast Cancers?Semantic proximity Read ↗

Triple-negative breast cancer: current state of the art.Semantic proximity Read ↗

Discovery and evaluation of novel biomarkers reveal dasatinib as a potential treatment for a specific subtype of Triple-Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.